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Abbreviations 
AMN  Acquired melanocytic nevi 
CNA copy number aberration 
COSMIC Catalogue of somatic mutations in cancer 
CPDs cyclobutane pyrimidine dimers 
LOH loss-of-heterozygosity 
OIS oncogene-induced senescence 
SNV single-nucleotide variants 
TPM TERT promoter mutations 
UVR ultra-violet radiation 
WES whole-exome sequencing 
URLs 
COSMIC mutation signature analysis:  http://cancer.sanger.ac.uk/cosmic/signatures   
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ABSTRACT 
The melanoma transformation rate of each nevus is rare despite the detection of oncogenic 
BRAF or NRAS mutations in 100% of nevi. Acquired melanocytic nevi (AMN) do however 
mimic melanoma and ~30% of all melanomas arise within pre-existing nevi. Using whole-
exome sequencing of 30 matched nevi, adjacent normal skin, and saliva we sought to identify 
the underlying genetic mechanisms for nevus development. All nevi were clinically, 
dermoscopically, and histopathologically documented. In addition to identifying somatic 
mutations, we found mutational signatures relating to ultra-violet radiation (UVR) mirroring 
those found in cutaneous melanoma. In nevi we frequently observed the presence of the UVR 
mutation signature compared to adjacent normal skin (97% vs 10% respectively). In copy 
number aberration (CNA) analysis, in nevi with copy number loss of tumor suppressor genes 
(TSG), these were balanced by loss of potent oncogenes. Moreover, reticular and non-
specific patterned nevi revealed an increased (p<0.0001) number of CNA as compared with 
globular nevi. The mutation signature data generated in this study confirms that UVR 
strongly contributes to nevogenesis. Copy number changes reflect at a genomic level the 
dermoscopic differences of AMN. Lastly, we propose that the balanced loss of TSGs and 
oncogenes is a protective mechanism of AMN. 
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INTRODUCTION 
Melanocytic nevi are acquired benign neoplasms of the skin derived from melanocytes. In 
both children and adults, new nevi can form and existing ones change regularly (Abbott et al., 
2014, Duffy et al., 2004, Menzies et al., 2011) which can be closely monitored for diagnostic 
purposes in melanoma screening. Many benign melanocytic lesions are excised unnecessarily 
as most nevi, even with a change in morphology, will never develop into a melanoma. 
Despite the rarity of transformation of an individual nevus (Tsao et al., 2003), it has been 
reported that ~30% (range; 4-72%) of melanoma have arisen from a pre-existing nevus 
(Pampena et al., 2017) hence the reasoning for close monitoring. Indeed, Shain et al. (Shain 
et al., 2015) showed that in archival clinical specimens, which had a melanoma adjacent to a 
nevus, that there were many shared mutations and copy number aberrations consistent with a 
linear pathway from melanocyte to transformed precursor to melanoma. However, the 
conundrum still exists in that ~70% of melanomas arise de novo (Pampena et al., 2017) 
without any histopathological evidence for a precursor lesion. Improving the understanding 
of nevus development and transformation is therefore the key to understanding the etiology 
of melanoma and more efficient prevention and early detection methods for this increasingly 
common malignancy.  
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RESULTS AND DISCUSSION 
Study sample and somatic mutation burden in nevi 
Using whole-exome sequencing (WES) we assessed the somatic mutational landscape, 
mutation signatures and copy-number aberrations (CNA) in 30 acquired pigmented 
melanocytic nevi and matching adjacent normal skin (perilesional). The prospectively 
collected nevi were classified clinically as having a globular (n=12) or reticular/non-specific 
(n=18) pattern and were histopathologically diagnosed (DL) as benign/dysplastic lesions with 
common architectural features (Table S1). Somatic single-nucleotide variants (SNVs) were 
identified in all nevi lesional tissue from the exome pull-down region (coding and 
untranslated regions) with ranges from 30-668 mutations (median, 256) or 0-9 mutations per 
megabase (muts/Mb). The total number of deleterious mutations (nonsense and 
nonsynonymous) ranged from 13-340 SNVs (median, 89) which is higher than those 
previously described in a study of 19 dysplastic nevi (range 0-46; median, 19) (Melamed et 
al., 2017). The observed differences are likely due to the sample populations with all of our 
nevi derived from a population that have a history of frequent sun exposure combined with a 
geographical region that has one of the highest level of UVR in the world (Brisbane, 
Australia). 
Somatic single-nucleotide variant subclasses in nevi and matching perilesional skin  
Not surprisingly, C>T transitions were confirmed to be the most prevalent SNV class (Fig. 
1a) and subsequent investigation into the tri-nucleotide context (e.g. N[C>T]N) showed that 
overall the nevi analysed here share many similarities to the mutation frequency distribution 
in cutaneous melanoma (see Materials and Methods) (Fig. 1b). The point of difference 
between nevi and melanomas can be seen with the ratio of T[C>T]G:T[C>T]C being higher 
in melanoma (Fig. 1b). Interestingly, this increase in T[C>T]G transitions corresponds to the 
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presence of deleterious mutations in tumor suppressor genes such as ARID2, ATM, DCC, and 
NF1; all of which are absent in our nevi and in nevi analysed by Melamed et al (Melamed et 
al., 2017). This supports the notion that loss of tumor suppressor gene function contributes to 
melanomagenesis. 
In matching perilesional skin, C>T transitions were again the most prevalent (Fig. 1c) yet this 
did not match the mutation profile observed in nevi (Fig. 1d-e). Given the proportion of C>T 
SNVs accounts for the majority of the variants observed, we next chose to focus on these 
variant types. When dermoscopic patterns were compared, globular nevi had a significantly 
(p=0.013) higher proportion of T[C>T]A transitions cf. reticular/non-specific nevi (Fig. 2a). 
When histopathologic were compared, it was revealed that intradermal nevi had a 
significantly increased amount of G[C>T]C and T[C>T]A variants (p=0.03 and p=0.04 
respectively) cf. junctional/compound nevi (Fig. 2b) (see Table S1 for corresponding 
details). These data indicate that the differences observed in the dermoscopic patterns can be 
related to their histopathological classification with the globular nevi in our dataset having 
primarily a dermal component. Importantly, there were no significant differences in C>T 
transitions in dysplastic cf. benign nevi which suggests that the broad and non-specific 
classification of ‘dysplastic’ nevi is inaccurate. Overall, these data suggest that specific 
mutation types may contribute to the development of distinct dermoscopic and 
histopathologic nevus phenotypes. 
Driver gene analysis in nevi 
Previous studies have used a targeted gene approach to identify likely ‘driver’ genes in 
amongst a sea of ‘passenger’ genes (Cheng et al., 2015, Shain et al., 2015).   Using a 
combined gene list from these studies, the number of driver genes that harboured a 
deleterious mutation present in our nevi ranged from 1-14 (Table S2). Mutually exclusive 
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mutations in BRAF and NRAS were the most frequent (83% and 17% respectively) which is 
in keeping with our prior study using droplet digital PCR (Tan et al., 2018). Other genes of 
note included MET with three mutations (10%; NM_000245: Glu266Lys, Pro712Thr, and 
Gly1151Arg), and GRIN2A with two mutations (7%; NM_000833: Arg899Trp and 
Pro1132Leu). Targeted gene panels allow for a focused approach but are limited to 
identifying known genes. In addition to these well-known genes, we identified genes such as 
HDAC9 (NM_058176: p.Ser612Phe), MYH11 (NM_002474:p.Gly743Glu), and DCC 
(NM_005215: p.Asp866Asn) which were flagged as predicted driver mutations using 
IntOGen (Gonzalez-Perez et al., 2013) (Table S3). Interestingly these ‘driver’ mutations are 
present at a similar variant allele frequency as BRAFV600E and BRAFV600K respectively which 
indicate that they most likely occurred at the same time during nevus formation. Notably, 
BRAF mutations have been observed to occur in all cells present in a nevus, as such nevi are 
considered to be clonal, originating from a single initiated melanocyte (Yeh et al., 2013). 
However alternative to this, is the theory that nevi are not always clonal but can be polyclonal 
(Lin et al., 2009). In our study, we find evidence for both notions (Table S2) although in 
most cases where a BRAF mutation appears in a ‘clonal’ nevus, other gene mutations co-
occur at a similar mutation frequency as noted (Tables S2 and S3). In cases where BRAF 
mutations occur at a sub-clonal frequency (< % nevus cell estimate), it is unclear if this is due 
to a late acquisition of the BRAF mutation or an observation of oncogene-induced senescence 
(OIS) (Michaloglou et al., 2005) in the initial nevus cell population followed by an outgrowth 
of cells that have acquired a selective advantage via a new mutation. Given that BRAF V600 
mutations are the most prevalent, they are likely to be the initiator and the other genes contain 
private deleterious mutations that provide a permissive environment for nevus development. 
TERT promoter mutation analysis in nevi 
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TERT promoter mutations (TPM) are prevalent in melanoma (60-86%) (Cancer Genome 
Atlas, 2015, Hayward et al., 2017, Horn et al., 2013, Huang et al., 2013) and have also been 
observed in ‘intermediate’ melanocytic lesions (Shain et al., 2015) that occur adjacent to a 
melanoma. We did not detect any of the common TPMs (data not shown) in our benign or 
dysplastic lesions which was not an unexpected finding considering there was no evidence 
for malignant transformation observed clinically or histopathologically. 
Mutation signature analysis in nevi and matching perilesional skin 
The underlying causative mechanisms for most of the common malignancies investigated to 
date can be elucidated by analysing somatic mutation signatures (Alexandrov et al., 2013). 
Each unique signature is named “signature 1-30” and is defined by the pattern and proportion 
of specific trinucleotides present in each sample (see COSMIC mutation signature URL for 
definitions). In cutaneous melanoma, it has been established that UVR creates a well-known 
somatic mutation signature (“signature 7”). We confirm that the predominance of C>T 
transitions observed in our nevi resulted in a prevalent proportion of signature 7 related SNVs 
(97% or 29/30; range 0-82%, median 61%; Fig. 3a and Table S4). Three of the 30 nevi 
(10%) had a low signature 7 proportion (0-13%; Tables S1 and S4) which correlated with no 
or limited UVR exposure based upon body location and clinical evidence of sun exposure. 
This suggests that acquired melanocytic nevi are not always initiated via UVR exposure. An 
age-related signature (signature 1) (Alexandrov et al., 2013) was the next most prevalent 
(93% or 28/30; range 0-61%, median 26%; Fig. 3a and Table S4). However we could find no 
significant association with signature 1 with age at lesion excision (data not shown). 
Remarkably, two samples had no signature 1 along with a low or absent signature 7 (13% and 
0% respectively). Instead of these common signatures, evidence for defective DNA mismatch 
repair (Alexandrov et al., 2013) was identified (signature 20; 23% and signature 6, 13% 
respectively). This highlights an alternative mechanism for nevi development in the absence 
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of UVR. Defects in DNA repair is in fact prevalent in our nevi (10/30 or 33%) with many 
mutually exclusive signatures being identified (signatures 3, 6, 15, 20, and 26) (Alexandrov 
et al., 2013) (Fig. 3a and Table S1 and S4) which confirms that defective DNA repair 
contributes to nevogenesis. 
Recent studies have established that sun-exposed skin derived from the eyelid have an excess 
of C>T mutations in a targeted panel of genes (Martincorena et al., 2015). Using WES we 
were able to determine the somatic mutations present in 30 matching normal skin samples 
(Table S5). We too observed a predominance of C>T mutations, however surprisingly this 
did not culminate into a UVR signature in all samples (10% or 3/30; Fig. 3b). Defective 
DNA repair signatures (signatures 3 and 26) (Alexandrov et al., 2013) were however 
frequently observed (83% and 50% respectively) along with signature 1 (100%). 
These mutation signature data suggest a number of scenarios. Firstly, the accumulation of 
age-related mutations and defective DNA repair machinery, lead to the accumulation of UVR 
signature mutations in a given melanocyte, which contributes to nevogenesis. Secondly, the 
absence of the classical UVR signature mutations in the perilesional skin which predominates 
in the more pigmented (and thus more melanin containing) nevi, suggests that the melanin 
content may contribute to the excess of C>T transitions specific to the UVR signature. This 
notion is supported by the study by Premi et al. (Premi et al., 2015) which described that the 
many of cyclobutane pyrimidine dimers (CPDs) arise via the breakdown of melanin pigment. 
Somatic mutation type and mutation signature analysis of nevi relative to body 
location/degree of sun exposure 
Next we investigated nevi located on different body sites in combination with clinical 
evidence of sun exposure. Indeed, nevi located on ‘shielded’ sites (Table S1) were 
significantly (p=0.006) more likely to have a higher proportion of insertion/deletions (indels) 
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(Fig. 4a) as compared with nevi located on ‘sun exposed’ sites which were more likely 
(p=0.03) to have a higher proportion of deleterious mutations.  Not surprisingly, nevi from 
sun-exposed sites had a higher proportion of signature 7 mutations (p=0.001) (Fig. 4a) which 
is consistent with UVR contributing to high somatic mutation burden. Moreover, in nevi that 
had a signature 7 profile that was less than the observed median (61%); these nevi were more 
likely (p=0.014) to have a defective DNA repair signature (Fig. 4b) which in turn was more 
likely (p=0.045) to be present in dysplastic nevi (Fig. 4c). Interestingly, there was no 
significant differences (data not shown) in the different dermoscopic patterned nevi based on 
degree of body site/sun exposure, the proportion of signature 7 or DNA repair defect 
signatures, or the proportion of deleterious mutations present. However reticular/non-specific 
nevi where more likely (p=0.002) to have a higher proportion of indels (Fig 4d) cf. globular 
nevi which may suggest an alternative mechanism for development. 
Copy number aberration analysis of nevi 
In addition to high somatic mutation burden, cutaneous melanomas have an increased amount 
of copy number aberrations (CNA). Specifically, melanomas often have focal deletions in 
tumor suppressor genes (e.g. CDK2NA), focal amplifications in oncogenes (e.g. MITF), 
along with extensive regions of copy number loss-of-heterozygosity (LOH) often 
encompassing whole chromosomal arms (Stark and Hayward, 2007). Complex genomic 
rearrangements are also the hallmark of non-UVR induced mucosal and acral melanomas 
(Hayward et al., 2017). Interestingly, our dermoscopically globular nevi were largely 
genomically silent with minor CNAs observed (Fig. 5a), however in stark contrast we 
detected a high frequency of genome-wide CNAs in our reticular/non-specific nevi 
(p<0.0001; Fig 5b; Table S6-7) which correlates with the higher proportion of observed 
indels. Considering the extensive nature of the CNAs present in the reticular/non-specific 
nevi, one would assume that this may herald the early beginnings of a melanoma. However, 
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upon closer inspection of the genes involved, the CNAs appear to be balanced events. 
Importantly, the majority of the observed CNAs were large regional CNAs (mainly LOH) 
rather than focal regions of loss which is a hallmark of cutaneous melanoma. These large 
regional events suggest that no specific gene is being targeted; instead this is a random 
mutagenic process. To find evidence for LOH events effecting gene expression, interrogation 
of the melanoma TCGA data (Cancer Genome Atlas, 2015) revealed that on average, LOH of 
key melanoma genes can significantly result in a loss of expression in tumor suppressors as 
well as in oncogenes (Fig. S1 and S2). We therefore postulate that the net effect of the loss of 
both gene functions in the same nevus specimen combine to have an overall copy neutral 
effect, thus keeping the nevus in a state of equilibrium so as to be ‘protected’ against 
malignant transformation. 
In summary, this study has highlighted that acquired nevi occur in most cases following 
cumulative exposure to UVR together with defective DNA repair mechanisms in normal skin 
melanocytes. This environment permits the accumulation of UV-related somatic mutations 
which is evident in the mutation signatures (Table S1, S4, and Figure 6) observed in our nevi 
and matching adjacent skin. Moreover, we predict that CNA events that are balanced (or 
absent) in clonally expanded melanocytes, lead to the nevogenesis pathway. Lastly, if these 
CNA events become imbalanced in a given clonal expansion, then this contributes to the 
formation of early melanomas.  
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MATERIALS AND METHODS 
Patients and tissue sampling 
This study was approved by the Metro South Human Research Ethics Committee (Brisbane, 
Australia; HREC/09/QPAH/162) and was carried out in accordance with the Declaration of 
Helsinki. With written informed consent, 30 acquired melanocytic nevi with the globular 
(n=12), reticular (n=14) and non-specific (n=4) dermoscopic patterns identified by a board 
certified dermatologist (HPS) from a database of prospectively imaged nevi (Daley et al., 
2016) were excised by shave excision from 20 participants. Of these 10 donated a single 
nevus and the following 10 participants had two nevi excised: 07LW, 28RH, 111CM, 158RP, 
61JB, 510AN, 673PS, 736TP, 822MT, and 1346KJ, (Table S1). Each nevus was bisected 
and one half of the tissue was formalin-fixed and histopathologically diagnosed by a board 
certified pathologist (DL). The second half of the tissue was dissected to isolate nevus from 
adjacent perilesional skin according to methods previously described (Tan et al., 2018). DNA 
extraction was performed as described previously (Tan et al., 2018). Saliva was collected and 
germline DNA was extracted from each study participant as previously described (Daley et 
al., 2016). 
Somatic variant calling and filtering 
Somatic variants present in the nevi and perilesional samples were determined firstly by 
filtering out all variants that were present in the matching saliva-derived germline DNA 
followed by all variants that were present in 1000g2014oct_eur and ExAC NFE databases. 
Variants present in dbSNP 138 were not used as a filter due to the presence of somatic 
mutations (eg. BRAFV600E). Accordingly, a proportion of the variants presented in Tables S3 
and S5 may indeed be polymorphisms. Next, any variant present in a pool of 30 perilesional 
samples were removed from each the nevi samples which resulted in a list of somatic variants 
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present only in the lesion and not from perilesional contamination. Next, all somatic variants 
present in the nevi and perilesion were filtered further to include only those with a total of 
≥10 reads, an alternative read frequency of ~3% (based upon known a mutation in NRASQ61K 
previously determined by ddPCR (Tan et al., 2018)), a variant p≤0.05, and an alternate Phred 
base quality of 30. 
Detection of known mutations 
In order to test the sensitivity of the exome sequencing depth for identifying somatic 
mutations in BRAF or NRAS present in our nevi samples (Tan et al., 2018), we first used The 
Integrative Genome Viewer (IGV, Broad Institute) to visualise the BAM files at specific 
codons. BRAF V600E/K mutations were detectable in all samples (26/26; Table S2) and 
NRAS G13C and Q61L/K/R were detectable in the remaining 4/4 samples (Table S2). The 
digital PCR methodology employed in our prior study (Tan et al., 2018) detected additional 
NRAS G13C mutations in samples with codon 61 mutations which were not detectable in our 
exome dataset as they were less than the limit of detection (~1% mutant frequency). 
Furthermore, the NRAS Q61L mutation detected in 903JA-33 via exome sequencing was not 
validated using ddPCR and instead was found to have an NRAS G13C mutation. The NRAS 
Q61L is possibly a false positive result. Next, we confirmed the presence of the validated 
mutations in the stringently filtered dataset as described. BRAF/NRAS mutations were 
detectable in 17/30 samples with 13/30 not passing filtering due to low mutant allele 
frequency (10/13) and were filtered out during variant calling; or the mutant call had a  
p>0.05 (3/13) as determined via VarScan2 (Koboldt et al., 2012). 
TERT promoter sequence analysis 
The TERT promoter region was amplified using forward (5’- 
ACGAACGTGGCCAGCGGCAG-3’) and reverse (5’- CTCCCAGTGGATTCGCGGGC-3’) 
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primer sequences designed using Primer3web (v4.0.0) software. To increase the specificity of 
the primers, a touchdown PCR protocol was employed with a cycling routine of two cycles at 
each annealing temperature commencing at 69°C, decreasing by 1°C steps (69°C-63°C), 
followed by 20 cycles at the optimal temperature (62°C). All other cycling conditions were as 
per manufacturers protocol (Thermo Fisher Scientific). PCR reactions consisted of 25-50ng 
of DNA, 0.5µM of each primer, 200µM dNTPs (Thermo Fisher Scientific), together with 
0.4U of Phusion Hot start II High-Fidelity DNA polymerase (#F-549, Thermo Fisher 
Scientific), 5X Phusion GC buffer (supplemented with MgCl2; #F-519) and 5% DMSO. The 
369bp PCR products were electrophoresed on a 2% TAE agarose gel, purified using the 
QIAquick Gel Extraction Kit (QIAGEN), then sequenced using the BigDye™ Terminator 
v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific) as per manufacturer’s instructions. 
Agencourt CleanSEQ (Beckman Coulter Life Sciences) purified products were run on the 
3730-series Genetic Analyzer (Thermo Fisher Scientific) by the Australian Equine Genetics 
Research Centre (AEGRC, Brisbane, Australia). All TERT promoter sequence 
chromatograms were analyzed using Sequencher 5.4 software (Gene Codes Corporation) in 
comparison with hg19 reference sequence (chr5: 1,295,022-1,295,495). 
Mutation signature analysis 
Filtered somatic SNVs present in the nevi and perilesional skin were imported into the 
deconstructSigs (Rosenthal et al., 2016) package using R 3.4.0 for Windows 
(https://github.com/raerose01/deconstructSigs). Mutation signatures were determined by 
using the framework of 30 Cosmic signatures (http://cancer.sanger.ac.uk/cosmic/signatures) 
collated in the deconstructSigs package. Somatic mutations present in melanoma datasets 
were downloaded from 
ftp://ftp.sanger.ac.uk/pub/cancer/AlexandrovEtAl/somatic_mutation_data/Melanoma/ and 
imported into the deconstructSigs package as described. 
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Copy Number Analysis 
Copy number aberrations were determined via the CNVkit (Rieber et al., 2017) package 
(https://github.com/etal/cnvkit) and run using Python 2.7. Briefly, matching nevi and 
perilesion BAM files, with duplicates marked and sorted (see methods above) where analysed 
within CNVkit according to standard methods. The matching perilesion was used as the 
background normal. Nevus cell content was estimated based upon BRAF mutation frequency 
as determined by methods previously reported (Shain et al., 2015). In the absence of BRAF 
mutation, tumor cell fraction was estimated from H&E sections by an experienced 
dermatopathologist (HPS). A segmentation file (Table S6) was compiled from all lesions to 
allow for genome-wide visualisation (Figure 5) in the IGV. Genes involved in regions of 
gain (log2 ≥3) and loss (log2 ≤-1) summarised in Table 1, were those commonly mutated in 
melanoma (Cancer Genome Atlas, 2015). The effect of copy number on RNA expression in 
exemplar genes derived from Table 1 and shown in Supplementary Figures 1 and 2 was 
determined using the melanoma TCGA datasets accessed via the cBioPortal for Cancer 
Genomics (http://www.cbioportal.org/) (Cerami et al., 2012, Gao et al., 2013).  
Statistical Analysis 
Box plots and statistical analysis and was performed using 2-tailed t-tests (Mann-Whitney), 
or Fisher's exact test with GraphPad Prism version 7.03 for Windows (La Jolla, California, 
USA) or SPSS Statistics v.24 (IBM, USA). A p-value <0.05 was considered statistically 
significant. 
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FIGURE LEGENDS 
Figure 1: Single nucleotide variants (SNV) present in nevi and matching adjacent skin 
compared to cutaneous melanoma 
(a) Box and whisker plots (5-95th percentile) of the percentage of the 6 SNV classes (C>A, 
C>G, C>T, T>A, T>C, and T>G) somatically observed in melanocytic nevi (n=30). (b) Bar 
graph of the median C>T trinucleotide context# proportion observed in melanocytic nevi 
(n=30) is highly correlative with those observed in cutaneous melanoma (n=396). (c) Box 
and whisker plots (5-95th percentile) of the percentage of the 6 SNV classes somatically 
observed in perilesional skin samples (adjacent to melanocytic nevi) (n=30). (d) Bar graph of 
the median C>T trinucleotide context proportion observed in perilesional skin samples 
(n=30) highlighting the low correlation compared with nevi and melanoma (b). (e) Bar graph 
of the median 96 trinucleotide mutation profile observed in nevi (n=30) and matching 
perilesional skin (n=30). 
# T[C>T]G is an example of a C>T trinucleotide context which can alternatively be written as 
TCG>TTG 
Figure 2: The trinucleotide context of C>T SNVs in different dermoscopic and 
histopathological subtypes of nevi 
Box and whisker plots (min to max) of the percentage of C>T variant types that reached 
statistical significance (p<0.05) when dermoscopic and histotype subtypes of nevi were 
compared (Mann-Whitney U-test). (a) Nevi classified as globular have a significantly 
(p=0.0132) higher proportion of T[C>T]A transitions cf. reticular/non-specific nevi  and (b) 
intradermal nevi have a significantly increased amount of G[C>T]C and T[C>T]A variants 
(p=0.03 and p=0.04 respectively) cf. junctional/compound nevi. P values are indicated on 
graphs. 
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Figure 3: Mutation signatures present nevi and matching adjacent skin 
Box and whisker plots (5-95th percentile) of the percentage of the common COSMIC 
mutation signatures (n=30) present in our (a) nevi (n=30) and (b) matching perilesional skin 
(n=30). For description of COSMIC mutation signatures please refer to the URL 
http://cancer.sanger.ac.uk/cosmic/signatures. 
Figure 4: Somatic mutation type and mutation signature of nevi relative to body 
location/degree of sun exposure 
(a) Insertion deletion mutations are more commonly found in sun-shielded nevi (p=0.0062) 
and sun exposed nevi are more likely to have deleterious mutations (p=0.03) and a higher 
proportion of signature 7 mutations (p=0.0013). (b) The total number of nevi that have a 
signature 7 mutation profile < the median (61%) are more likely to have defective DNA 
repair signatures present (p=0.0142). (c) Dysplastic nevi are more likely to have a defective 
DNA repair signatures (p=0.045) present while there are no significant differences in 
signature 7 mutations relative to benign nevi. (d) Reticular/non-specific patterned nevi are 
more likely to have an insertion deletion mutation (p=0.0017) whilst there is no significant 
difference in deleterious mutations between dermoscopic subtypes. P values are indicated on 
graphs. ns = p>0.05. 
Figure 5: Copy number aberrations in different dermoscopic patterned nevi 
Genome-wide copy number aberrations (CNAs) in dermoscopic patterned (a) globular and 
(b) reticular/non-specific nevi. Globular nevi are largely genomically silent with minor CNAs 
observed (a) and reticular/non-specific nevi have significantly (p<0.0001) more CNAs with 
mostly large regional LOH events being present. Chromosomes are represented from left to 
right in chromosomal order. Dark blue = copy number equivalent to homozygous deletion 
(HD or deep deletion); Light blue = copy number equivalent to loss of heterozygosity (LOH 
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or shallow deletion); Light red = copy number equivalent to 3 copies (gain); and Dark red = 
copy number equivalent to >3 copies (amplified). 
Figure 6: Model for the fate of clonally expanded skin melanocytes 
Somatic mutation signature and copy number aberration (CNA) analysis allows for insights 
into nevogenesis. This model shows that normal skin melanocytes accumulate mutations if 
there are defects in normal DNA-repair mechanisms. Over time, clonal expansion occurs and 
in most cases forms a benign nevus which has balanced CNA events thereby protected 
against malignant transformation. If imbalanced CNA events occur, then the clonally 
expanded melanocytes follow the melanomagenesis pathway. Melanoma can directly arise 
from a benign nevus or via the intermediate neoplasm state. 
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